ArticleESMO open2026

Efficacy and safety of pembrolizumab-lenvatinib in metastatic endometrial cancer: results from the French multicenter early access program.

D Bello Roufai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.